AI assistant
Sanofi — Capital/Financing Update 2010
Apr 8, 2010
1643_iss_2010-04-08_941cc73c-58c9-48cc-85cf-6529bd9004bd.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFERING OF SECURITIES IN THE UNITED STATES OF AMERICA. THE NOTES MAY NOT BE OFFERED, SOLD OR DELIVERED IN THE UNITED STATES OF AMERICA, EXCEPT PURSUANT TO REGISTRATION OR AN EXEMPTION FROM REGISTRATION REQUIREMENTS UNDER OR PURSUANT TO THE U.S. SECURITIES ACT OF 1933, AS AMENDED. SANOFI-AVENTIS DOES NOT INTEND TO REGISTER THE PROPOSED OFFERING IN WHOLE OR IN PART IN THE UNITED STATES OF AMERICA OR TO CONDUCT A PUBLIC OFFERING IN THE UNITED STATES OF AMERICA.
Sanofi-aventis successfully completes a tap on its October 2014 bond for 500 million Euros
Paris, France – April 8, 2010 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) - rated AA- by Standard & Poor's and A1 by Moody's – announced today the issuance of a tap on its October 10, 2014 bond in the amount of 500 million Euros, increasing the total principal amount of this bond to EUR 1.2 billion.
This issue is made under the Company's Euro Medium Term Note Programme.
The main characteristics of the tap are as follows:
Principal Amount: 500 million Euros Coupon: 3.125% Issue Price: 102.667% Maturity: October 10, 2014
Given a price of 102.667%, the cost of financing amounts to 2.488%, lower by 0.7 points than the inaugural bond issue of this same maturity.
This document is an advertisement and not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council of November 4th, 2003 (as implemented in each Member State of the European Economic Area (the "Member States"), the ("Prospectus Directive")).
***
No action has been or will be undertaken to make an offer to the public of the notes described above.
The Base Prospectus dated April 1, 2010 relating to the Programme has been approved by the Commission de Surveillance du Secteur Financier in Luxembourg. This prospectus has not been and will not be passported in another Member State in relation to the above mentioned issue pursuant to the Prospectus Directive.
This press release may only be communicated to persons in the United Kingdom in circumstances where section 21(1) of the Financial Services and Markets Act 2000 does not apply.
Sanofi-aventis: www.sanofi-aventis.com Media Relations: Tél. : (+) 33 1 53 77 44 50 - E-mail : [email protected] Investor Relations : Tél. : (+) 33 1 53 77 45 45 - E-mail : [email protected]